Physician profile
Igor Siniakov
NPI 1053430272
$2,171.69
in general payments reported to CMS, 2019-2025
36 companies · $992 in 2025
The $992 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.69 · 2020: $29.46 · 2021: $260 · 2022: $539 · 2023: $62.77 · 2024: $248 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.60 |
| Education | $239.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $392.52 | 2019-2022 | |
| Legend Biotech USA INC. | $273.22 | 2025 | Carvykti |
| Regeneron Healthcare Solutions, INC. | $177.48 | 2021-2025 | Libtayo, Lynozyfic |
| Janssen Biotech, INC. | $130.12 | 2024-2025 | Rybrevant, Carvykti, Darzalex |
| Amgen INC. | $121.31 | 2019-2022 | |
| Genzyme Corporation | $110.14 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $78.01 | 2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $71.77 | 2024-2025 | |
| Leo Pharma INC. | $68.15 | 2022 | |
| Incyte Corporation | $60.33 | 2024-2025 | Monjuvi, Jakafi |
| Pharmacosmos Therapeutics INC. | $52.96 | 2025 | Monoferric |
| Sobi, INC | $45.82 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.76 | 2024-2025 | Iclusig, Ninlaro |
| Genentech USA, INC. | $39.54 | 2025 | Itovebi, Tecentriq |
| Sun Pharmaceutical Industries INC. | $35.92 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $34.21 | 2025 | |
| Novo Nordisk INC | $32.53 | 2023-2024 | Rybelsus, Ozempic |
| Alexion Pharmaceuticals, INC. | $31.73 | 2025 | Ultomiris |
| Kyowa Kirin, INC. | $26.88 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $26.70 | 2021-2022 | |
| Pfizer INC. | $26.24 | 2022 | |
| Adaptive Biotechnologies Corporation | $24.80 | 2025 | Clonoseq |
| Daiichi Sankyo INC. | $24.67 | 2025 | Enhertu |
| Array Biopharma INC | $24.62 | 2025 | Braftovi, Tukysa, Mektovi |
| Puma Biotechnology, INC. | $22.00 | 2024 | |
| Geron Corporation | $21.98 | 2025 | Rytelo |
| Organogenesis INC. | $21.45 | 2025 | Novachor |
| Myriad Genetic Laboratories, INC. | $21.08 | 2025 | Prolaris |
| Dendreon Pharmaceuticals LLC | $18.80 | 2025 | Provenge |
| Celltrion USA INC. | $18.25 | 2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $17.48 | 2025 | Keytruda |
| Bayer Healthcare Pharmaceuticals INC. | $16.88 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $16.26 | 2023 | Crysvita |
| Biogen, INC. | $15.97 | 2023 | Vumerity, Tysabri |
| Nuvation Bio INC. | $13.78 | 2025 | Ibtrozi |
| Tg Therapeutics, INC. | $13.33 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Siniakov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.